At BIOOCUS International Treatment Center, we are proud to introduce Hemo-cel, a groundbreaking gene therapy that offers new hope for patients suffering from sickle cell disease (SCD) and transfusion-dependent thalassemia (TDT). Hemo-cel is designed to address the root cause of these conditions, providing a potential cure through a one-time treatment.
What is Hemo-cel?
Hemo-cel is an advanced gene therapy that uses the patient’s own hematopoietic stem and progenitor cells (HSPCs), which are genetically modified to produce healthy hemoglobin. By correcting the faulty gene responsible for these blood disorders, Hemo-cel can dramatically improve patients' lives, potentially eliminating the need for regular blood transfusions and offering a lifelong solution.
How Does Hemo-cel Work?
Stem Cell Collection:
HSPCs are collected from the patient’s blood.
Genetic Modification:
The cells are enhanced outside the body using a lentiviral vector that introduces a modified β-globin gene.
Reinfusion:
The genetically modified cells are reinfused back into the patient, where they begin to produce healthy red blood cells capable of generating functional hemoglobin.
Restoring Balance:
This process restores the balance between α-globin and β-globin chains in the blood, effectively reducing symptoms of anemia and enabling patients to achieve transfusion independence.
Proven Results
Clinical trials of Hemo-cel have shown remarkable success:
100% of patients achieved successful bone marrow engraftment.
Most patients became transfusion-independent within weeks after the therapy.
One patient has been transfusion-free for nearly four years without significant side effects.
The therapy also helps alleviate iron overload, a common complication in TDT patients who undergo regular transfusions.
Why Choose Hemo-cel?
A Safer Alternative
Unlike traditional treatments like hematopoietic stem cell transplantation (HSCT), which requires a donor match and carries risks such as graft-versus-host disease (GVHD), Hemo-cel uses the patient’s own cells. This eliminates the need for a donor match and reduces the risk of complications, making the treatment safer and more accessible.
Global Availability
Having achieved significant success in China, Hemo-cel is now expanding globally. With clinical partnerships in Saudi Arabia, Thailand, Malaysia, and other countries, we are committed to making this innovative treatment accessible to patients worldwide.
A Future Without Transfusions
Hemo-cel offers a promising future for those affected by SCD and beta-thalassemia. Imagine a life free from constant blood transfusions, with the potential for a permanent cure. At BIOOCUS, we are dedicated to making this vision a reality through cutting-edge gene therapy solutions like Hemo-cel.
Contact Us Today
If you or a loved one is living with sickle cell disease or thalassemia, Hemo-cel could be the solution you’ve been waiting for. Contact us today to learn more about how Hemo-cel can transform your treatment journey and offer a brighter, healthier future.
